Biosimilar Antibodies

Bectumomab (IMMU-LL 2) is a humanized IgG2a monoclonal antibody specifically targeting human CD22, an antigen predominantly expressed on the surface of B cells. This antibody is engineered as an anti-lymphoma agent, primarily utilized in the detection and management of non-Hodgkin's lymphoma (NHL). Bectumomab is compatible for use in imaging studies when conjugated with technetium-99 (Tc99m LL2 Fab), facilitating the assessment of lymphoma staging in both recurrent and newly diagnosed cases. Additionally, it serves as a valuable tool in evaluating the efficacy of targeting prior to the initiation of radioimmunotherapy (RIT). This antibody's specificity and application in advanced diagnostic imaging and therapy make it a critical component in lymphoma research and clinical practice.

Prolgolimab (BCD-100) is a human IgG1 monoclonal antibody targeting the PD-1 receptor, incorporating an Fc region modified with the 'LALA' mutation to silence effector functions. This antibody is utilized in research focused on advanced melanoma, providing a valuable tool for investigating the immunological pathways involved in tumor progression and response to therapy.

The Anti-FOLR1/FRA Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the FOLR1/FRA protein. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 146.46 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This antibody is applicable for use in various immunological assays to study the role and expression of the FOLR1/FRA protein in biological systems.

Elsilimomab (B-E8) is an IgG1 monoclonal antibody that targets interleukin-6 (IL-6), exhibiting a dissociation constant (KD) of 22 pM and an inhibitory concentration (IC50) of 1.4 nM. This antibody is utilized in research focused on multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA), providing a valuable tool for investigating the role of IL-6 in these conditions.

Pasritamig is a bispecific antibody designed to target KLK2 and CD3E. It is structured as a (H-γ1_L-κ)_scFvkh-G1(h-CH2-CH3) type, combining specificity to both antigens. This configuration enhances its application in directing immune system components to tumor cells expressing KLK2, thereby facilitating targeted immunotherapy. Pasritamig is primarily used in research focused on cancer therapy modalities, particularly in studies investigating prostate cancer and immune cell engagement mechanisms.

PF-5212374 (TRU-015) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CD20 (MS4A1). This antibody features a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with a molecular weight of approximately 145 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Tegoprubart is a monoclonal antibody specifically targeting the CD40 ligand (CD40L), an essential component of immune system costimulation. By inhibiting CD40L, Tegoprubart effectively diminishes both cellular and antibody-mediated immune responses, facilitating the creation of a more tolerant immune environment. This antibody has demonstrated significant in vivo efficacy in various transplantation animal models, underscoring its potential utility in immune modulation and transplant medicine.

Lirilumab (IPH2102) is a monoclonal antibody targeting KIR (Killer-cell Immunoglobulin-like Receptors), demonstrating significant antitumor activity. This antibody is specifically designed for research applications focusing on leukemia and squamous cell carcinoma of the head and neck (SCCHN), providing a valuable tool for studies aimed at understanding and potentially modulating immune responses in these cancers.

Ruxoprubart is a human monoclonal antibody of the IgG1κ subtype designed to specifically target complement factor B (CFB). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

XmAb 5592 is a humanized, Fc-engineered monoclonal antibody targeting HM1.24, designed to enhance binding affinity to FcγRIIIa and FcγRIIa receptors. This antibody facilitates increased lysis of HM1.24-specific multiple myeloma (MM) cells through both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) in vitro. This specificity and mechanism of action make XmAb 5592 a valuable tool for research into therapeutic interventions for multiple myeloma.

Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody designed to target integrin αIIbβ3. It exhibits potent antiplatelet and antithrombotic properties, making it an ideal candidate for research into cardiovascular diseases. Tadocizumab's specificity for integrin αIIbβ3 allows for the study of this integrin's role in platelet aggregation and thrombus formation, providing valuable insights into potential therapeutic approaches for thrombotic disorders.

Labetuzumab is a humanized monoclonal antibody targeting the carcinoembryonic antigen (CEA), known for its role in inhibiting tumor growth. This antibody has demonstrated efficacy in sensitizing human medullary thyroid cancer xenografts to Dacarbazine, enhancing the chemotherapeutic response. Labetuzumab is utilized primarily in research focused on the treatment and mechanistic understanding of cancer progression and therapy resistance.

Panitumumab (ABX-EGF) is a fully human IgG2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), exhibiting potent anti-tumor properties. This antibody effectively inhibits tumor cell proliferation, survival, and angiogenesis, making it a valuable tool for cancer research, particularly in studies focused on colon cancer.

Datopotamab (CDP7657) is a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2). This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), particularly when conjugated with the DNA topoisomerase I inhibitor, Deruxtecan. Datopotamab is primarily utilized in research focused on triple-negative breast cancer and non-small cell lung cancer, providing a valuable tool for investigating therapeutic avenues in these challenging oncological contexts.

The Anti-ANO1/TMEM16A Antibody is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target ANO1/TMEM16A, a calcium-activated chloride channel implicated in various physiological processes. This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control, it is recommended to use Human IgG1 kappa, Isotype Control, to aid in distinguishing specific from non-specific binding.

The Anti-Orai1 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Orai1 protein. This antibody is composed of a human IgG2 heavy chain and a human lambda light chain, with an approximate molecular weight of 150 kDa. For isotype control, the Human IgG2 kappa, Isotype Control is recommended. This product is essential for studies focusing on the role of Orai1 in calcium channel function and its implications in immune response and various cellular processes.

The Anti-CXC-ELR Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the CXC-ELR motif. This antibody is composed of a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For use as an isotype control, the Human IgG4 kappa, Isotype Control is recommended. This product is ideal for research applications requiring precise targeting of the CXC-ELR motif.

Inlecitug is a chimeric monoclonal antibody designed to target the human kinase insert domain receptor (KDR). By specifically binding to KDR, Inlecitug effectively blocks the interaction between vascular endothelial growth factor (VEGF) and KDR, subsequently inhibiting angiogenesis. This inhibition plays a crucial role in exerting antitumor activity, making Inlecitug a valuable tool for cancer research.

The Anti-TNFSF9/4-1BBL Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells that specifically targets TNFSF9, also known as 4-1BBL. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control purposes, researchers should use the Human IgG1 kappa, Isotype Control. This antibody is ideal for studies focusing on the biological activities and interactions of TNFSF9/4-1BBL in immune regulation and cancer immunotherapy research.

Vamikibart is a chimeric humanized monoclonal antibody of the IgG2κ isotype, specifically designed to target interleukin 6 (IL-6). This antibody is engineered for high specificity and affinity in neutralizing IL-6, a cytokine involved in various inflammatory and autoimmune processes. Vamikibart is suitable for use in research focused on the role of IL-6 in disease mechanisms and therapeutic interventions.

Mavrostobart is a human monoclonal antibody of the IgG4κ isotype that specifically targets NT5E (CD73). For experimental control purposes, the recommended isotype control is Human IgG4 (S228P) kappa. This antibody is designed for precise binding to NT5E, making it highly relevant for research into its role in immunoregulation and tumor progression.

The Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody specifically designed to target the c-Met receptor, also known as hepatocyte growth factor receptor (HGFR). This antibody is recommended for use with Human IgG1 kappa as an isotype control to ensure specificity and accuracy in experimental results.

Amatuximab (MORab-009) is a chimeric, humanized IgG1/k monoclonal antibody designed to specifically target mesothelin (MSLN), a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein. Mesothelin is expressed in a limited range of normal adult tissues, predominantly in the mesothelium. This antibody binds to the cell surface mesothelin, making it a valuable tool for research into mesothelin's role in various biological processes and diseases.

Cedelizumab (RWJ 49004) is an IgG4 monoclonal antibody designed to specifically target CD4, a glycoprotein expressed on the surface of immune cells such as T helper cells. This antibody exhibits immunosuppressive properties, making it a valuable tool for research into immune response modulation and potential therapeutic applications in autoimmune diseases and transplant rejection.

MK-4166 is a humanized IgG1 monoclonal antibody designed as an agonist targeting the glucocorticoid-induced TNFR-related protein (GITR). This antibody facilitates the enhancement of proliferation in both naïve and tumor-infiltrating T lymphocytes, making it a critical tool in the study of T cell dynamics and cancer immunotherapy. MK-4166's specificity for GITR and its agonistic properties position it as a valuable agent for research focused on immune response modulation within oncological environments.

Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody designed to specifically target the insulin-like growth factor 1 receptor (IGF-1R). This antibody functions by inhibiting the signaling pathways initiated by IGF-1 and IGF-2, which are commonly implicated in tumor cell proliferation. It effectively blocks IGF-1R autophosphorylation and subsequent phosphorylation of Akt, a critical node in the pro-survival signaling network. Additionally, Dalotuzumab promotes apoptosis and induces cell cycle arrest, further inhibiting cancer cell growth. Research has demonstrated that when used in conjunction with other anticancer agents, including statins, Dalotuzumab exhibits enhanced antitumor efficacy both in vitro and in vivo. This makes it a valuable tool for studies focused on cancer biology and therapeutic antibody development.

Exbivirumab is a monoclonal antibody specifically targeting the hepatitis B virus (HBV). This antibody is designed to augment the antiviral efficacy of hepatitis B immunoglobulin (HBIG), providing a potentiated response against HBV infections. Exbivirumab is pivotal in research focused on the development of more effective therapeutic protocols for hepatitis B, offering a promising tool for both basic research and clinical applications.

Lesofavumab (MHAB5553A) is a humanized IgG1κ monoclonal antibody specifically targeting the influenza B virus. This antibody is designed for high specificity and affinity in binding to influenza B antigens, making it an essential tool for research focused on viral pathogenesis, immune response, and potential therapeutic interventions for influenza B infections.

Recibokibart is a humanized IgG1κ monoclonal antibody specifically targeting IL1RL2. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Navenibart is a humanized IgG1κ monoclonal antibody specifically targeting KLKB1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Bapineuzumab is a monoclonal antibody targeting the β-amyloid protein (APP), specifically designed for Alzheimer’s disease research. This antibody binds to the β-amyloid plaques, which are a hallmark of Alzheimer’s pathology, making it an essential tool for studies focused on disease mechanisms and potential therapeutic interventions.

Fasinumab is a human IgG4 monoclonal antibody specifically targeting nerve growth factor (NGF). This antibody is utilized in research focused on acute sciatica and knee osteoarthritis, providing a valuable tool for studies investigating the role of NGF in pain and inflammation associated with these conditions.

Sasanlimab (PF-06801591) is a humanized IgG4-κ monoclonal antibody designed to selectively target the Programmed Death-1 (PD-1) receptor. This antibody is produced in Chinese Hamster Ovary (CHO) cells, ensuring high fidelity and consistent performance in immunotherapy research. Sasanlimab is primarily utilized in studies focused on the modulation of immune checkpoints, which are critical for advancing cancer immunotherapy.

Elranatamab (PF-06863135) is a human IgG2κ monoclonal antibody targeting CD3E and TNFRSF17. For optimal experimental control, it is recommended to use Human IgG2 kappa as an isotype control.

Pelgifatamab (BAY-2315497) is a monoclonal antibody targeting the prostate-specific membrane antigen (PSMA). This antibody can be covalently attached to a 225Ac binding moiety, making it a valuable tool for research into metastatic castration-resistant prostate cancer (mCRPC). Pelgifatamab's specificity for PSMA and its potential for radioisotope conjugation facilitate its use in advanced prostate cancer studies, particularly in therapeutic research and radiolabeled imaging applications.

Minretumomab (CC-49) is a murine monoclonal antibody that targets TAG-72 (tumor-associated glycoprotein 72), a protein frequently overexpressed in various carcinomas. This antibody is extensively utilized in the study of cancer biology and immune response mechanisms, providing valuable insights into tumor markers and the development of therapeutic strategies.

Tuvirumab (OST 577; SDZ-OST 577) is a monoclonal antibody of the human IgG1 subclass, specifically targeting the hepatitis B virus surface antigen (HBsAg). It binds with high specificity and affinity, exhibiting a dissociation constant (Kd) of 3.6 nM for HBsAg. This antibody is primarily utilized in the study of chronic hepatitis B, offering significant potential for research applications in this area.

Izuralimab is a bispecific IgG1 monoclonal antibody designed for simultaneous targeting of the inducible T-cell costimulator (ICOS/CD278) and the programmed death-1 receptor (PD-1). This dual specificity facilitates a coordinated modulation of T-cell responses, enhancing immune activation against tumors while potentially mitigating autoimmune responses. Izuralimab is utilized predominantly in oncological research to investigate therapeutic strategies for enhancing antitumor immunity.

Netakimab is a monoclonal antibody targeting interleukin-17 (IL-17). This biologic is specifically designed for research applications related to ankylosing spondylitis, psoriatic arthritis, and moderate-to-severe plaque psoriasis. Netakimab's mechanism of action involves the inhibition of IL-17, a key cytokine involved in the inflammation and pathogenesis of various autoimmune disorders. This makes it a valuable tool for studies aiming to understand and potentially modulate immune responses in these conditions.

ABP 215 (Bevacizumab-awwb), a biosimilar to Bevacizumab, is a humanized IgG1 monoclonal antibody that specifically targets vascular endothelial growth factor A (VEGFA), thereby inhibiting its interaction with VEGF receptors. This antibody demonstrates anticancer properties by impeding angiogenesis, a critical process in tumor growth and metastasis. ABP 215 is utilized in research focused on metastatic colorectal cancer (mCRC), providing a valuable tool for investigating disease mechanisms and potential therapeutic interventions.

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody of the IgG4 subtype, designed to exhibit potent neutralizing and internalizing capabilities. This antibody effectively inhibits both hepatocyte growth factor (HGF)-dependent and HGF-independent MET pathway activations, thereby impeding tumor growth. Emibetuzumab is primarily utilized in cancer research studies, focusing on its therapeutic potential and mechanism of action in oncogenic signaling and tumor progression.

Lixudebart is a humanized IgG1-kappa monoclonal antibody that specifically targets Claudin-1 (CLDN1). This antibody is designed for the study of CLDN1's role in tight junction integrity and its implications in various pathological conditions. Lixudebart's high specificity and affinity make it an ideal tool for detailed biochemical and cellular research applications.

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody designed to simultaneously target PD-1 and CTLA-4. By inhibiting these checkpoint pathways, Cadonilimab effectively alleviates immunosuppression and reverses T cell exhaustion specific to tumor environments. This antibody notably reduces Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Cadonilimab is applicable in research focused on metastatic cervical cancer and other malignancies, including gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, and non-small cell lung cancer (NSCLC), providing a valuable tool for investigations into immune checkpoint blockade and cancer immunotherapy.

Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

Izalontamab (SI-B001) is a bispecific monoclonal antibody designed to selectively target the EGFR/HER3 heterodimer, demonstrating high specificity in its binding affinity. This antibody is primarily utilized in cancer research, facilitating the study of molecular pathways and potential therapeutic interventions related to EGFR and HER3 interactions.

LY3022855 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CSF1R (Colony Stimulating Factor 1 Receptor), also known as M-CSFR or CD115. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Elarekibep (PRS-060/AZD1402) is a potent, long-acting full antagonist of the IL-4 receptor alpha (IL-4Ra), characterized by high affinity and slow dissociation rates. This agent is specifically designed for the study of Type 2 endotype asthma, providing a valuable tool for research into the pathophysiology and potential therapeutic interventions for this condition.

Moxetumomab is a human IgG1 κ monoclonal antibody targeting CD22. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Aprutumab (BAY 1179470) is a fully human monoclonal antibody targeting the fibroblast growth factor receptor 2 (FGFR2). It exhibits specific binding affinity to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. This antibody is primarily explored for its applicability in the study of solid tumors, offering significant potential for research into cancer biology and therapeutic development.